Delcath Systems, Inc. (DCTH) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $13.10, but acceptable to hold if already in. Reason: Near 52-week high (1.8% away).
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer... Read more
Hold if already holding. Not a fresh buy at $13.10, but acceptable to hold if already in. Reason: Near 52-week high (1.8% away). Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Mixed signals. Hold existing position. Score 6.5/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $13.10, but acceptable to hold if already in. Reason: Near 52-week high (1.8% away). Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Mixed signals. Hold existing position. Target $18.58 (+41.8%), stop $12.28 (−6.7%), A.R:R 2.7:1. Score 6.5/10, moderate confidence.
Take-profit target: $18.58 (+40.8% upside). Target $18.58 (+41.8%), stop $12.28 (−6.7%), A.R:R 2.7:1. Stop-loss: $12.28.
Near 52-week high (1.8% away).
Delcath Systems, Inc. trades at a P/E of 1320.0 (forward -25.9). TrendMatrix value score: 8.2/10. Verdict: Hold.
13 analysts cover DCTH with a consensus score of 4.2/5. Average price target: $21.
What does Delcath Systems, Inc. do?Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver...
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.